Art. -Nr.: HY-N2590

Lupenone

Kundenbewertung

Based on 1 Customer Validation

Lupenone is an orally active lupine-type triterpenoid that can be isolated from Musa basjoo. Lupenone Lupenone plays a role through the PI3K/Akt/mTOR and NF-κB signaling pathways. Lupenone has anti-inflammatory, antiviral, antidiabetic and anticancer activities.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.74%
CAS. Nr.: 1617-70-5
Formel: C₃₀H₄₈O
Molecular Weight:424.70

Speicherung:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Lupenone Chemical Structure

CAS. Nr.: 1617-70-5

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

Trypanosoma

Alle Parasite Isoform-spezifische Produkte anzeigen :

Alle PI3K Isoform-spezifische Produkte anzeigen :

Alle Akt Isoform-spezifische Produkte anzeigen :

Alle mTOR Isoform-spezifische Produkte anzeigen :

Alle NF-κB Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
B16	ED₅₀	0.35 μM Compound: 2	Induction of melanogenesis in mouse B16 2F2 cells assessed as intracellular melanin content after 3 days Induction of melanogenesis in mouse B16 2F2 cells assessed as intracellular melanin content after 3 days	[PMID: 12027734]
B16	IC₅₀	25.4 μM Compound: 2	Growth inhibition of mouse B16 2F2 cells after 3 days Growth inhibition of mouse B16 2F2 cells after 3 days	[PMID: 12027734]
CHO	EC₅₀	>10 μM Compound: Lupenone	Agonist activity at TGR5 expressed in CHO cells by CRE-driven luciferase reporter gene assay Agonist activity at TGR5 expressed in CHO cells by CRE-driven luciferase reporter gene assay	[PMID: 19911773]
COS-1	EC₅₀	0 μM Compound: Lupenone	Agonist activity at human FXR expressed in COS1 cells by luciferase reporter gene assay Agonist activity at human FXR expressed in COS1 cells by luciferase reporter gene assay	[PMID: 19911773]
DU-145	CC₅₀	>500 μM Compound: 4	Cytotoxic activity in human DU145 cells by sulforhodamine B assay Cytotoxic activity in human DU145 cells by sulforhodamine B assay	[PMID: 29120172]
DU-145	IC₅₀	>500 μM Compound: 4	Antiproliferative activity in human DU145 cells by sulforhodamine B assay Antiproliferative activity in human DU145 cells by sulforhodamine B assay	[PMID: 29120172]
HEK293	CC₅₀	>500 μM Compound: 4	Cytotoxic activity in HEK293 cells by sulforhodamine B assay Cytotoxic activity in HEK293 cells by sulforhodamine B assay	[PMID: 29120172]
HEK293	IC₅₀	>500 μM Compound: 4	Antiproliferative activity in HEK293 cells by sulforhodamine B assay Antiproliferative activity in HEK293 cells by sulforhodamine B assay	[PMID: 29120172]
HeLa	CC₅₀	>500 μM Compound: 4	Cytotoxic activity in human HeLa cells by sulforhodamine B assay Cytotoxic activity in human HeLa cells by sulforhodamine B assay	[PMID: 29120172]
HeLa	IC₅₀	>10 μg/mL Compound: lupenone	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 16038541]
HeLa	IC₅₀	>500 μM Compound: 4	Antiproliferative activity in human HeLa cells by sulforhodamine B assay Antiproliferative activity in human HeLa cells by sulforhodamine B assay	[PMID: 29120172]
HEp-2	CC₅₀	>500 μM Compound: 4	Cytotoxic activity in human Hep2 cells by sulforhodamine B assay Cytotoxic activity in human Hep2 cells by sulforhodamine B assay	[PMID: 29120172]
HEp-2	IC₅₀	>10 μg/mL Compound: lupenone	Cytotoxicity against human Hep2 cells after 48 hrs by MTT assay Cytotoxicity against human Hep2 cells after 48 hrs by MTT assay	[PMID: 16038541]
HEp-2	IC₅₀	>500 μM Compound: 4	Antiproliferative activity in human Hep2 cells by sulforhodamine B assay Antiproliferative activity in human Hep2 cells by sulforhodamine B assay	[PMID: 29120172]
J774.A1	IC₅₀	38.8 μM Compound: 2	Antiinflammatory activity in mouse J774A1 cells assessed as inhibition of LPS-induced NO production incubated for 1 hr prior to LPS challenge measured after 24 hrs by Griess method Antiinflammatory activity in mouse J774A1 cells assessed as inhibition of LPS-induced NO production incubated for 1 hr prior to LPS challenge measured after 24 hrs by Griess method	[PMID: 24909081]
KB	CC₅₀	>500 μM Compound: 4	Cytotoxic activity in human KB cells by sulforhodamine B assay Cytotoxic activity in human KB cells by sulforhodamine B assay	[PMID: 29120172]
KB	IC₅₀	>500 μM Compound: 4	Antiproliferative activity in human KB cells by sulforhodamine B assay Antiproliferative activity in human KB cells by sulforhodamine B assay	[PMID: 29120172]
L6	IC₅₀	>90 μM Compound: 10	Cytotoxicity against rat L6 cells after 72 hrs by microplate fluorimetry Cytotoxicity against rat L6 cells after 72 hrs by microplate fluorimetry	[PMID: 21438586]
MCF7	CC₅₀	>500 μM Compound: 4	Cytotoxic activity in human MCF7 cells by sulforhodamine B assay Cytotoxic activity in human MCF7 cells by sulforhodamine B assay	[PMID: 29120172]
MCF7	IC₅₀	>500 μM Compound: 4	Antiproliferative activity in human MCF7 cells by sulforhodamine B assay Antiproliferative activity in human MCF7 cells by sulforhodamine B assay	[PMID: 29120172]
MDA-MB-231	CC₅₀	>500 μM Compound: 4	Cytotoxic activity in human MDA-MB-231 cells by sulforhodamine B assay Cytotoxic activity in human MDA-MB-231 cells by sulforhodamine B assay	[PMID: 29120172]
MDA-MB-231	IC₅₀	>500 μM Compound: 4	Antiproliferative activity in human MDA-MB-231 cells by sulforhodamine B assay Antiproliferative activity in human MDA-MB-231 cells by sulforhodamine B assay	[PMID: 29120172]
RAW264.7	IC₅₀	>0.4 μM Compound: lupenone	Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide release after 24 hrs Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide release after 24 hrs	[PMID: 20192236]
RAW264.7	IC₅₀	38.5 μM Compound: 2	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 1 hr prior to LPS challenge measured after 24 hrs by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 1 hr prior to LPS challenge measured after 24 hrs by Griess method	[PMID: 24909081]
SiHa	CC₅₀	>500 μM Compound: 4	Cytotoxic activity in human SiHa cells by sulforhodamine B assay Cytotoxic activity in human SiHa cells by sulforhodamine B assay	[PMID: 29120172]
SiHa	IC₅₀	>500 μM Compound: 4	Antiproliferative activity in human SiHa cells by sulforhodamine B assay Antiproliferative activity in human SiHa cells by sulforhodamine B assay	[PMID: 29120172]
Vero	CC₅₀	>500 μM Compound: 4	Cytotoxic activity in African green monkey Vero cells by sulforhodamine B assay Cytotoxic activity in African green monkey Vero cells by sulforhodamine B assay	[PMID: 29120172]
Vero	IC₅₀	>10 μg/mL Compound: lupenone	Cytotoxicity against african green monkey Vero cells after 48 hrs by MTT assay Cytotoxicity against african green monkey Vero cells after 48 hrs by MTT assay	[PMID: 16038541]
Vero	IC₅₀	>500 μM Compound: 4	Antiproliferative activity in African green monkey Vero cells by sulforhodamine B assay Antiproliferative activity in African green monkey Vero cells by sulforhodamine B assay	[PMID: 29120172]

In Vitro

Lupenone (40 μM, 1 h) protects neuroblastoma SH-SY5y cells from methamphetamine-induced apoptotic cell death through PI3K/Akt/mTOR signaling pathway^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

SH-SY5y
Concentration:

5, 10. 20, 40 μM
Incubation Time:

24 h
Result:

Did not cause significant cell death at different concentrations.

Apoptosis Analysis^[1]

Cell Line:

SH-SY5y
Concentration:

40 μM
Incubation Time:

1 h
Result:

Reduced the population of annexinV/PI-positive cells (early apoptotic cells) and annexinV positive cells (total apoptotic cells).

Western Blot Analysis^[1]

Cell Line:

SH-SY5y
Concentration:

40 μM
Incubation Time:

1 h
Result:

Increased the expression of anti-apoptotic proteins, including bcl-2 and caspases such as caspase 3, caspase 7, and caspase 8.
Recuperate the phosphorylation level of PI3K and Akt.
Inhibited the translocation of p65 from the cytosol to the nucleus, IκBα degradation, and IκBα phosphorylation.

In Vivo

Lupenone (6, 12, 24 mg/kg/day, gavage for 6 weeks) improves type 2 diabetic nephropathy by regulating NF-κB pathway-mediated inflammation and TGF-β1/Smad/ CTGF-related fibrosis^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Spontaneous type 2 diabetic nephropathy db/db mouse models^[1]
Dosage:

6, 12, 24 mg/kg
Administration:

i.g.
Result:

Maintained the fasting blood glucose.
Reduced glycosylated hemoglobin, insulin, and 24 h proteinuria levels.
Regulated changes in biochemical indicators

Chemical Information

CAS. Nr. 1617-70-5
Appearance Solid
Molecular Weight 424.70
Formel C₃₀H₄₈O
Color White to off-white
SMILES

C[C@]12[C@@](CC[C@@]3([H])[C@]2(CC[C@](C4(C)C)([H])[C@@]3(CCC4=O)C)C)([H])[C@]5([H])[C@](C)(CC[C@H]5C(C)=C)CC1
Structure Classification
- Terpenoids
- Triterpenes
Initial Source
- Plants
- Compositae
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Lösungsmittel & Löslichkeit

In Vitro:

Ethanol : 10 mg/mL (23.55 mM; ultrasonic and warming and heat to 60°C)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.3546 mL

11.7730 mL

23.5460 mL

5 mM

0.4709 mL

2.3546 mL

4.7092 mL

10 mM

0.2355 mL

1.1773 mL

2.3546 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% EtOH 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 1 mg/mL (2.35 mM); Clear solution

This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (10.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% EtOH 90% Corn Oil

Solubility: ≥ 1 mg/mL (2.35 mM); Clear solution

This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (10.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (283 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Lee HS, et al. Lupenone Protects Neuroblastoma SH-SY5y Cells Against Methamphetamine-Induced Apoptotic Cell Death via PI3K/Akt/mTOR Signaling Pathway. Int J Mol Sci. 2020 Feb 27;21(5):1617. [Content Brief]

[2]. Wu H, et al. Lupenone improves type 2 diabetic nephropathy by regulating NF-κB pathway-mediated inflammation and TGF-β1/Smad/CTGF-associated fibrosis. Phytomedicine. 2023 Sep;118:154959. [Content Brief]

[3]. Mukerjee N, et al. Dynamics of natural product Lupenone as a potential fusion inhibitor against the spike complex of novel Semliki Forest Virus. PLoS One. 2022 Feb 25;17(2):e0263853. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
Ethanol	1 mM	2.3546 mL	11.7730 mL	23.5460 mL	58.8651 mL
	5 mM	0.4709 mL	2.3546 mL	4.7092 mL	11.7730 mL
	10 mM	0.2355 mL	1.1773 mL	2.3546 mL	5.8865 mL
	15 mM	0.1570 mL	0.7849 mL	1.5697 mL	3.9243 mL
	20 mM	0.1177 mL	0.5887 mL	1.1773 mL	2.9433 mL

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Lupenone

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

NF-κB Signaling Compound Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Antiviral Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Anti-diabetic Compound Library

Oxygen Sensing Compound Library

Medicine Food Homology Compound Library

Terpenoids Library

Glycolysis Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Antiparasitic Compound library

Anti-Cancer Metabolism Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Glucose Metabolism Compound Library

Anti-Cancer Natural Product Library

Antiviral Traditional Chinese Medicine Active Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Pain-Related Compound Library

Membrane Protein-targeted Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

Lactylation Compound Library

Alle Parasite Isoform-spezifische Produkte anzeigen

Alle PI3K Isoform-spezifische Produkte anzeigen

Alle Akt Isoform-spezifische Produkte anzeigen

Alle mTOR Isoform-spezifische Produkte anzeigen

Alle NF-κB Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Lupenone Related Classifications

HY-N2590 Related Classifications